With 1.59 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.9 million shares. The 52-week range on CDNA shows that it touched its highest point at $34.84 and its lowest point at $9.64 during that stretch. It currently has a 1-year price target of $28.62. Beta for the stock currently stands at 2.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CDNA was down-trending over the past week, with a drop of -21.79%, but this was down by -17.94% over a month. Three-month performance dropped to -38.61% while six-month performance fell -35.92%. The stock gained 52.97% in the past year, while it has lost -33.77% so far this year. A look at the trailing 12-month EPS for CDNA yields 1.15 with Next year EPS estimates of 0.17. For the next quarter, that number is -0.10. This implies an EPS growth rate of -137.81% for this year and 146.92% for next year.
Float and Shares Shorts:
At present, 55.46 million CDNA shares are outstanding with a float of 51.81 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CDNA since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.79979 being high and -$1.0283 being low. For CDNA, this leads to a yearly average estimate of -$0.895.
